Review
Materials Science, Multidisciplinary
Chung-Sung Lee, Rajendra K. Singh, Hee Sook Hwang, Na-Hyun Lee, Amal George Kurian, Jung-Hwan Lee, Hye Sung Kim, Min Lee, Hae-Won Kim
Summary: Severe injuries and diseases of bone tissue pose challenges for complete recovery. Materials-based nanotherapeutics can address issues related to therapeutic molecule delivery, ultimately improving effectiveness and reducing off-target concerns.
PROGRESS IN MATERIALS SCIENCE
(2023)
Review
Oncology
George M. Viola, Ariel D. Szvalb, Alexandre E. Malek, Anne-Marie Chaftari, Ray Hachem, Issam I. Raad
Summary: The article comprehensively reviews evidence-based recommendations and best practices for the prevention of device-related infections. It emphasizes the importance of collaboration between various entities and the need for sustained reduction in infection rates.
CA-A CANCER JOURNAL FOR CLINICIANS
(2023)
Article
Immunology
Tariq Azamgarhi, Ashik Shah, Simon Warren
Summary: The study demonstrated that implementing the findings of the OVIVA trial into clinical practice, with follow-up by an established OPAT service for patients on oral antibiotics, is safe and effective. Two-thirds of patients were switched to suitable oral antibiotic regimens, leading to reductions in hospital length of stay and antibiotic costs.
CLINICAL INFECTIOUS DISEASES
(2021)
Article
Oncology
Philipp Winnand, Mark Ooms, Marius Heitzer, Matthias Lammert, Frank Hoelzole, Ali Modabber
Summary: This study demonstrated the real-time detection of bone-invasive oral cancer using laser-induced breakdown spectroscopy (LIBS), which may establish a rapid bone analysis method. The replacement of calcium (Ca) by potassium (K) and sodium (Na) can distinguish healthy and tumorous tissue. Further development of a LIBS-guided assessment of bone tumor resection margins might reduce bony resection extent without compromising oncologic safety.
Review
Biochemistry & Molecular Biology
Luca Ambrosio, Maria Grazia Raucci, Gianluca Vadala, Luigi Ambrosio, Rocco Papalia, Vincenzo Denaro
Summary: Bone cancer is a challenging disease with currently limited curative treatments. The burden of adverse events and subsequent disability is a major concern, highlighting the need for innovative biomaterials to selectively inhibit cancer progression while preserving healthy bone properties.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2021)
Article
Biotechnology & Applied Microbiology
Tianfei Ran, Chuanchuan Lin, Tianying Ma, Yinyin Qin, Jie Li, Yuan Zhang, Yuan Xu, Changqing Li, Min Wang
Summary: This study designed an ultra-pulsed CO2 laser osteotomy system and verified its safety at the tissue and cell levels through animal experiments, comparing it with the traditional mechanical saw. The results showed that the ultra-pulsed CO2 laser could achieve non-invasive bone cutting with no thermal damage to the bone tissue, and it also had advantages in cell adhesion and infiltration.
FRONTIERS IN BIOENGINEERING AND BIOTECHNOLOGY
(2022)
Article
Orthopedics
Manabu Kawata, Taisuke Jo, Shuji Taketomi, Hiroshi Inui, Ryota Yamagami, Hiroki Matsui, Kiyohide Fushimi, Hideo Yasunaga, Sakae Tanaka
Summary: This study identified novel risk factors for SSI after HTO, such as the use of artificial bone grafts and longer anesthesia duration, as well as novel protective factors including a primary diagnosis of osteonecrosis and younger age. These findings will aid surgeons in assessing the risk of SSI after HTO in individual patients.
KNEE SURGERY SPORTS TRAUMATOLOGY ARTHROSCOPY
(2021)
Review
Oncology
Marta Masini, Matteo Toma, Paolo Spallarossa, Italo Porto, Pietro Ameri
Summary: RCTs have demonstrated that rivaroxaban, edoxaban, and apixaban are equally effective as LMWH in treating CAT, but increase the risk of major gastrointestinal bleeding. Apixaban and rivaroxaban can also prevent CAT in high-risk chemotherapy patients, but may lead to higher bleeding likelihood. Limited data is available for using DOAC in individuals with intracranial tumors or thrombocytopenia, and drug interactions with anticancer agents may affect DOAC effectiveness-safety profile. Current guidelines recommend DOAC as the first-line anticoagulants for CAT, but caution should be exercised in specific patient subgroups.
CURRENT ONCOLOGY REPORTS
(2023)
Article
Oncology
Rogerio Jardim Caldas, Heliton Spindola Antunes, Camila de Oliveira Rodini Pegoraro, Fabio Ribeiro Guedes, Paulo Sergio da Silva Santos
Summary: The study found that cancer patients exposed to bisphosphonates for at least 7 months with poor oral health condition are more likely to develop medication-related osteonecrosis of the jaw. Patients with osteonecrosis typically have multiple decayed teeth, gingival problems, and periodontal disease. Oral infections seem to play a major role in the development of bone necrosis.
SUPPORTIVE CARE IN CANCER
(2021)
Article
Veterinary Sciences
R. A. Leal, N. E. Lambrechts, J. D. Crowley, J. F. Griffin, J. J. Karnia, B. T. Torres, K. C. Maritato, N. R. Kieves, F. M. Duerr
Summary: This study aimed to compare the ability of five radiographic scoring systems to identify changes in bone healing following TPLO and evaluate the influence of limb positioning on TPLO osteotomy scoring. The VAS system was found to be the most appropriate for identifying small changes in bone healing, and the positioning of postoperative radiographs had a significant impact on the healing score assigned.
FRONTIERS IN VETERINARY SCIENCE
(2023)
Article
Oncology
Piers D. Mitchell, Jenna M. Dittmar, Bram Mulder, Sarah Inskip, Alastair Littlewood, Craig Cessford, John E. Robb
Summary: By analyzing skeletal data from 6 cemeteries in the Cambridge area, the study found that the prevalence of cancer in medieval Britain at the time of death was approximately 9% to 14%, compared to 40% to 50% in modern Britain. This suggests that cancer was much less common in medieval times than it is today.
Review
Pediatrics
Alba Ferrandez-Pujante, Amparo Perez-Silva, Clara Serna-Munoz, Jose Luis Fuster-Soler, Ana Ma Galera-Minarro, Inmaculada Cabello, Antonio J. Ortiz-Ruiz
Summary: The aim of this study was to update existing research on oral care in children diagnosed with cancer. The use of standardized protocols can reduce oral cancer complications and the side effects of cancer therapies.
Article
Microbiology
Loren G. Miller, Evelyn A. Flores, Bryn Launer, Pamela Lee, Praneet Kalkat, Kelli Derrah, Shalini Agrawal, Matthew Schwartz, Grant Steele, Tae Kim, Maita S. Kuvhenguhwa
Summary: Bone and joint infections are common and often lack safe and effective oral treatment options for Gram-positive infections. This study evaluated the safety and efficacy of oral tedizolid for the treatment of bone and joint infections in 44 patients. Detailed safety monitoring was conducted weekly for up to 12 weeks. The study found that tedizolid was well-tolerated and did not cause any cytopenias or neuropathy. The cure rates were similar to other studies on bone and joint infections. In conclusion, oral tedizolid appears to be a well-tolerated option for treating Gram-positive bone and joint infections.
MICROBIOLOGY SPECTRUM
(2023)
Article
Microbiology
Loren G. Miller, Evelyn A. Flores, Bryn Launer, Pamela Lee, Praneet Kalkat, Kelli Derrah, Shalini Agrawal, Matthew Schwartz, Grant Steele, Tae Kim, Malta. S. Kuvhenguhwa
Summary: This study investigated the safety and cure rate of oral tedizolid for the treatment of bone and joint infections (BJIs). The study found that oral tedizolid was well tolerated and had no significant toxicity when used for prolonged BJI treatment.
MICROBIOLOGY SPECTRUM
(2023)
Article
Cell & Tissue Engineering
M. A. F. Bendtsen, M. Bue, P. Hanberg, J. Slater, M. B. Thomassen, J. Hansen, K. Soballe, K. Obrink-Hansen, M. Stilling
Summary: This study compared the maintenance time of free flucloxacillin concentration above the minimum inhibitory concentration in soft and bone tissue after intravenous and oral administration in a porcine model. The results showed that intravenous administration achieved longer fT > MIC compared to oral administration, particularly in maintaining the concentration for bone tissue.
BONE & JOINT RESEARCH
(2021)